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Conclusions.– This suggests that BoNT-A induces spinal plasticity leading to
the recovery of reciprocal inhibition, which is likely to be due to the withdrawal
of inhibitory control from Renshaw cells directly blocked by BoNT-A. This
could help in limiting ankle muscle cocontractions in the transition phase from
stance to swing, to assist dorsiflexion.
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Background.– The therapeutic effects of intramuscular injections of botulinum
toxin type A (BTx) on spasticity can be largely explained by its blocking action
at the neuromuscular junction. BTx is assumed to also have a central action by
affecting the functional organization of the CNS. The aim of the present study is
to assess the action of BTx on spinal motor networks by investigating the post-
activation depression (post-AD) of the soleus H-reflex in post-stroke patients
presenting lower limb spasticity.
Methods.– Soleus H-reflex was investigated in chronic hemiplegic patients
before and 3, 6, 12 weeks after BTx-injections in soleus. H-reflex amplitude
was analyzed in response to electrical stimulation of the tibial nerve at 0.1 Hz
and 0.5 Hz. Post-AD was quantified as the ratio H0.5Hz/H0.1Hz.
Results.– The post-AD was significantly reduced in the affected side compared
to the non-affected side before BTx injection. Three weeks after injection,
the post-AD was reinforced in the paretic leg and significantly higher than in
pre-injection condition.
Conclusions.– BTx-treatment restores the post-AD of soleus H-reflex in post-
stoke paretic patients. As post-AD amount is correlated to the severity of
spasticity, it can be assumed that BTx’s effectiveness in post-stroke rehabilitation
is also due to induced-changes in spinal motor networks.
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Background.– Compare muscle length, spasticity angle and active range of
motion in adult paretic syndromes due to lesions acquired in infancy vs adult-
acquired lesions.
Methods.– Cross sectional study from a retrospective chart review.
Population.– Convenience sample of 2 groups of clinic patients with spastic
paresis due to an infant lesion (IL, n = 11) or to an adult-acquired lesion (AL,
n = 11).
Evaluation.– Muscle length (XV1), angle of catch (XV3), spasticity angle
(X = XV1–XV3), active range of motion (A) and angle of weakness (XV1–A) in
soleus, gastrocnemius, gluteus maximus, hamstrings, vastus and rectus femoris
muscles at the initial evaluation (pre-toxin).
Results.– The IL group had shorter muscle lengths in gluteus maximus (XV1,
IL, 101 ± 5; AL, 120 ± 5◦; P = 0.02, Mann–Whitney) and hamstrings (XV1, IL,
31 ± 7◦; AL, 63 ± 5◦, P = 0.004), smaller spasticity angles (X, gluteus maxi-
mus, IL, 7 ± 3◦; AL, 15 ± 4◦, P = 0.04; hamstrings, IL, 19 ± 4◦ vs AL, 42 ± 7◦,
P = 0.02) and smaller angle of weakness across all muscles studied (P = 0.04,
Wilcoxon). A was strongly correlated with XV1 across all muscles in the IL group
(P < 0.05) while this was only true for plantar flexors and gluteus maximus in
the AL group.
Conclusions.– Passive mechanical obstacles have greater impact on motor defi-
ciencies in infant paresis than in adult acquired lesions.
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Background.– The safety profile of onabotulinumtoxinA for treatment of upper
limb spasticity (ULS) was assessed across a range of doses to evaluate treatment
with ≥ 400 U.
Methods.– Integrated data from 18 studies of onabotulinumtoxinA for ULS were
evaluated by 4 dose groups (< 150 U, 150–250 U, 251–399 U, ≥ 400 U). Treat-
ment exposure, incidence of adverse events (AEs), serious AEs, and possible
distant spread of toxin (PDSOT) were assessed, together with the safety profile of
patients who received 4 consecutive onabotulinumtoxinA ≥ 400 U treatments.
Results.– Overall, 1342 patients received ≥ 1 onabotulinumtoxinA treatment;
183 received ≥ 400 U, with 6.6% (88/1330), 12.3% (115/936), 23.3% (113/486),
and 31.2% (96/308) in treatment cycles 1–4, respectively. AE rates were similar
across dose groups, with no consistent increase in incidence of any individual
AE/serious AE and no evidence of PDSOT at doses ≥ 400 U across treatment
cycles. The overall AE rate among the subset of patients (n = 51) with 4 conse-
cutive ≥ 400 U treatments was similar (43.1%, 43.1%, 43.1%, 41.2%), with no
overall change in profile for AEs/serious AEs with increasing treatments.
Conclusions.– OnabotulinumtoxinA at doses ≥ 400 U was well tolerated in ULS
patients, with no consistent pattern of increase in AEs at doses ≥ 400 U, reported
systemic AEs, or change in safety profile over consecutive treatments.
http://dx.doi.org/10.1016/j.rehab.2014.03.162
P203-e
Interests of medical hypnosis during toxin
botulinic injections: Preliminary study
S. Burlot a,∗, B. Casalonga b, C. Metivier a, A. Bioy c,
D. Lejeune a, P. Lesage a, P. Dediego a, D. Chane-Teng a
a CRF Ylang, Clinique du PORT-Jeanne d’ARC, Le Port
b CHU Réunion Bellepierre
c Laboratoire de Psychopathologie et Psychologie Médicale (LPPM–EA 4452)
Université de Bourgogne
∗Corresponding author.
Keywords: Toxin; Spasticity; Hypnosis; Pain
Background.– Our study concerns the efficiency of hypnosis during the injections
of botulinum toxin. Hypnosis is widely used in medicine to decrease the anxiety
and the painful felt, but few publications are appeared in physical medicine and
rehabilitation.
Methods.– In this bi-centrique study, the injections are practised at 30 patient’s
spastics. Two groups are constituted: the group “hypnosis” (standards analge-
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sic + hypnosis) and the group “witness” (standards analgesic). The patients gave
their agreement to participate in the study and participate in the choices of the
analgesic methods. The evaluation was performed at the end of the session and
during follow-up.
Results.– Certain are in progress: anxiety, pain felt during the injection, and
reactivity to needle seems better in the group hypnosis. The comfort of the
practitioner is globally improved, function of its experience in hypnosis
Conclusions.– Hypnosis has its place in our practice concerning the pains cause
by interventions, which is common in PRM practice. It requires one, however,
one unwound by the different care including information around the hypnosis
and an induction of the latter. Profits with regard to these arrangements are
discussed.
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Background.– Spasticity is a disabling consequence of stroke and traumatic
brain injury and contributes to other conditions, such as pain, impairment in
daily activities and gait. OnabotulinumtoxinA has been shown to reduce muscle
tone in patients with lower limb spasticity (LLS). We sought to assess whether
reducing muscle tone is associated with clinically meaningful improvements in
patient-related outcomes.
Methods.– Data from 3 published placebo-controlled LLS trials
(AGN/HO/SPA/001-191622 (BOTOX Economic Spasticity Trial [BEST]),
BTOX-702-8051, BTX108512) using onabotulinumtoxinA and the Patient
Registry Outcomes in Spasticity (PROS) World registry were indirectly
compared for patient-related outcomes.
Results.– A total of 509 patients were identified with LLS involving the ankle.
The patient clinical global impression scale was significantly* correlated with
modified Ashworth scale scores in BTX108512. Eighty percent of patients in
PROS were satisfied with their injections. BEST was significant* for the pro-
portion of patients reporting 50% reduction in pain. Significant* improvements
in spasms, cramps, and patient-rated injection benefit were demonstrated in
BTOX-702-8051 with strong trends in gait speed. Functional goal attainment
was significant* in BEST with improvements in PROS.
Conclusions.– Reductions in muscle tone after onabotulinumtoxinA treatment
are beneficial to patients as demonstrated by improvement in patient-related
outcomes.
*P < 0.05 vs placebo for ≥ 1 post-treatment time point.
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Background.– An illustrative picture guide to identify common postures of upper
and lower limb spasticity was developed for use by clinicians and patients.
Methods.– Five specialists in spasticity managment provided guidance on the
most common postures observed in patients with spasticity. A photo shoot with
patients was held to capture photos of these spasticity postures across four etio-
logies (stroke, traumatic brain injury, multiple sclerosis, and cerebral palsy).
Initially, clinicians separately ranked the most representative photo for each
posture. Subsequently, the group reached a consensus on the best photo for each
posture. A medical illustrator converted the posture photos into representative
sketches for inclusion into the picture tool.
Results.– Fifteen patients with spasticity representing each etiology participated
in the photo shoot. All postures were photographed from various angles, resul-
ting in at least five unique photos per posture. Fifteen common postures were
identified and converted into representative sketches.
Conclusions.– The spasticity common postures guide will be a useful tool
for determining the prevalence of spasticity postures and gaining a better
understanding of the treatment goals of spasticity presentations. Additio-
nally, the guide may reduce the heterogeneity of spasticity evaluation among
clinicans. Patients’ understanding of the guide will be evaluated in future inter-
views.
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Background.– Botulinum toxin (BoNT) injections are first-line treatment for
post-stroke spasticity (PSS). However, some patients may experience re-
emergence of symptoms before re-injection with a standard 12-weekly injection
regimen.
Methods.– Structured patient and physician surveys in Canada, France, Ger-
many, and USA. Patients had received ≥ 2 BoNT-A treatments for PSS.
Physicians had ≥ 3 years’ experience injecting BoNT for PSS. Information
regarding treatment satisfaction was collected from both groups.
Results.– Sixty-one of 79 patients (77%) received onabotulinumtoxinA, 15/79
(19%) abobotulinumtoxinA and 3/79 (4%) incobotulinumtoxinA. Most patients
were very (40.5%) or somewhat (48.1%) satisfied with BoNT treatment. Satis-
faction was highest at time of peak effect and lowest before re-injection. Injection
intervals ≤ 12 or ≤ 10 weeks were preferred by 78.9% or 43.4% of patients, and
received by 45.6% or 6.3%, respectively. Mean (standard deviation) injection
interval received was 13.7 (3.5) weeks. Physicians (n = 105) were modera-
tely (57.7%) or very (36.5%) satisfied with treatment, but felt that 16.2%
or 24.6% of patients would benefit from shorter intervals or higher doses,
respectively.
Conclusions.– Patient and physician satisfaction with BoNT treatment for PSS
is high, although patient preference is for shorter injection intervals. Physicians
believe shorter intervals and higher doses may confer additional benefit in some
patients.
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